- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03969862
Validation Study of NOVEOS® System (HYCOR) (HYCOR)
Validation Study of Noveos® System as a Diagnostic Tools for Allergy
Background : The NOVEOS® method is a chemiluminescent immunoassay used to provide quantitative detection of total IgE and allergen-specific IgE antibodies in human serum.
The IgE antibody assay has an essential place in the diagnosis of mediated IgE allergies.
This system could become an alternative to the techniques used today. NOVEOS® uses a quick and convenient method to give results concerning the patient's sensitization profile towards allergens. The volume required for the assays is 4 μl (against more than 100 μl for current techniques), which is particularly important in pediatric and geriatric populations where it may be more difficult to take larger samples.
NOVEOS® also brings true autonomy. In fact, the incorporated reagents provide sufficient capacity for 8 hours of continuous testing.
Objective: Validate the NOVEOS® system as an allergy diagnostic tool, by estimating the sensitivity and specificity of the NOVEOS® assays compared to the gold standard diagnostic represented by the clinical history and PT positive, for a panel of 20 allergens
Methods: This is a validation study of a new immunoassay method (Système NOVEOS®).
The study includes :
- A preliminary phase to familiarize the team with the use of the NOVEOS® system. It is planned to analyze its technical characteristics: the precision, the sensitivity. Eight allergens will be tested, on a cohort of 136 patients
- A validation study of the technique as a diagnostic tool for allergy (sensitivity and specificity compared to the gold standard represented by clinical history and positive PT) and comparison between the new technique and the ImmunoCap® system. Twenty allergens will be tested prospectively, each on 50 cases and 10 controls. A single patient may be both a case for an allergen and a witness for another. For rare allergies, the blood database of the Allergy Service will be used, and affected patients will be contacted to request their non-opposition.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Occitanie
-
Montpellier, Occitanie, France, 34295
- University Hospital of Montpellier
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
IncInclusion criteria:
- Patient who is at least 6 years old
- The patient must be an affiliate or beneficiary of a health insurance plan
Exclusion criteria:
- Patient refusing to take part in the study
- Patient participated in another study that may influence test results
- The patient is in an exclusion period determined by a previous study
- The patient is under the protection of justice, under guardianship or under curatorship
- Patient under antihistaminic H1 treatment preventing the achievement of Prick-tests
- The patient is pregnant
- The patient is breastfeeding
- The patient has a history of tumor, autoimmune, or immune deficiency pathology
- The patient suffers from a hematological pathology (coagulation disorders, anemia) that could interfere with the blood test
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patient with an allergen-mediated IgE allergy
Patients with a clinical history consistent with an allergen-mediated IgE allergy & with a sensitization demonstrated by a positive Prick-Test for the allergen source tested
|
The NOVEOS® System is a fully automated, high-throughput immunoassay platform that uses magnetic microbeads as a solid phase. This is a partially closed system that is primarily intended for the determination of specific IgE with NOVEOS® Hycor allergens. It has the CE mark. |
Patient without an allergen-mediated IgE allergy
Patient without a clinical history compatible with an IgE allergy-mediated allergy and without PT sensitization to be allergen
|
The NOVEOS® System is a fully automated, high-throughput immunoassay platform that uses magnetic microbeads as a solid phase. This is a partially closed system that is primarily intended for the determination of specific IgE with NOVEOS® Hycor allergens. It has the CE mark. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity and specificity of the NOVEOS® assay compared to the gold standard diagnosis.
Time Frame: 24 months
|
In order to validate the NOVEOS® system as an allergy diagnostic tool, We have to estimate the sensitivity and specificity of the NOVEOS® assays compared to the gold standard diagnostic represented by the clinical history and Prick Test positive, for a panel of 20 allergens.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Specific IgE assessed by NOVEOS®
Time Frame: 24 months
|
The serum-specific IgE assay is an in vitro assay of IgE antibodies that are able to bind specifically to their allergen. Today, there are techniques that allow the assay of both the IgE reactivity against sources of allergens, but also against the different allergenic components. The results of the NOVEOS® method will be considered acceptable according to the following criteria:
|
24 months
|
Specific IgE assessed by Thermo-Fisher ImmunoCAP®
Time Frame: 24 months
|
The serum-specific IgE assay is an in vitro assay of IgE antibodies that are able to bind specifically to their allergen. Today, there are techniques that allow the assay of both the IgE reactivity against sources of allergens, but also against the different allergenic components. There are already commercially available, validated and standardized methods; the most used is the Thermo-Fisher ImmunoCAP® (capable of detecting specific IgE amounts> 0.1 kUA / L). |
24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Pascal DEMOLY, MD,PHD, University Hospital, Montpellier
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 7572
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergen-mediated IgE Allergy
-
Philippe BéginThe Hospital for Sick Children; Centre de recherche du Centre hospitalier universitaire... and other collaboratorsRecruitingImmunotherapy | Physiological Effects of Drugs | Food IgE-mediated Allergy | OmalizumabCanada
-
Hospital San Carlos, MadridUnknown
-
Catholic University of the Sacred HeartMerck Sharp & Dohme LLCUnknown
-
Imperial College LondonUniversity of Sydney; National Institute for Health Research, United KingdomCompletedIgE Mediated Peanut AllergyUnited Kingdom
-
Assistance Publique - Hôpitaux de ParisFrench Society of Allergology; Stallergenes laboratories; Picot-Lactalis laboratory and other collaboratorsCompletedIgE Mediated Food AllergyFrance
-
Imperial College LondonUniversity College CorkActive, not recruitingPeanut Hypersensitivity | IgE Mediated Peanut AllergyUnited Kingdom
-
University of SouthamptonImperial College London; Natasha Allergy Research FoundationRecruitingPeanut Allergy | IgE-Mediated Cow Milk AllergyUnited Kingdom
-
Federico II UniversityRecruitingNon IgE Mediated Food Allergy | Food Protein-Induced Enteropathy | Food Protein-Induced Proctocolitis | Food Protein-Induced Enterocolitis Syndrome | Food Protein-induced Motility DisordersItaly
-
Assistance Publique - Hôpitaux de ParisCompletedQuality of Life and Eating Disorders in Children With FPIES, Food Allergy or Celiac Disease (QUALIM)Celiac Disease | FPIES | IgE Mediated Food AllergyFrance
-
King's College LondonKing's College Hospital NHS Trust; University College London Hospitals; Cambridge... and other collaboratorsRecruitingEgg Allergy | Food Allergy | Food Allergy in Children | Milk Allergy | Food Allergy in Infants | Nut Allergy | Food Allergen SensitisationUnited Kingdom
Clinical Trials on NOVEOS® system
-
CVRx, Inc.Completed
-
Prof. Dr. Carsten PerkaJulius Wolff InstituteUnknown
-
CereVasc IncAlvaMed, Inc.; Simplified Clinical Data Systems, LLC; Bioscience Consulting,...TerminatedPilot Study to Evaluate the CereVasc® eShunt® System in the Treatment of Communicating HydrocephalusHydrocephalus | Hydrocephalus, CommunicatingUnited States
-
VA Greater Los Angeles Healthcare SystemUniversity of California, Los AngelesRecruitingPost-Traumatic Stress DisorderUnited States
-
Global Kinetics CorporationRecruitingParkinson Disease | Movement DisordersUnited States
-
University of ZurichUniversity of Oxford; University of Padova; University Hospital, Zürich; Swiss... and other collaboratorsCompleted
-
Global Kinetics CorporationWithdrawn
-
Ulthera, IncCompleted